No Abstract BioWorld International CorrespondentPARIS - Trophos received €7 million (US$9.77 million) in funding for two projects involving the company's lead candidate, TRO19622, one of several cholesterol-oxime-based compounds it is developing for the treatment of neurodegenerative diseases.